Mga Batayang Estadistika
| CIK | 714256 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sanara MedTech Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| September 2, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Announces Chief Executive Officer Transition Seth Yon Appointed President, Chief Executive Officer and Director; Ron Nixon to Remain Executive Chairman FORT WORTH, TX, September 2, 2025 (GLOBE NEWSWIRE) - Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transfor |
|
| September 2, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), executed to be effective as of September 15, 2025 (the “Effective Date”), is entered into by and between Sanara MedTech Inc., a Texas corporation (“Sanara”, the “Company”, or the “Employer”), and Seth Yon (“Employee”). The Employer and Employee may be referred to singularly as “Party” or collectively as “Parties”. WITN |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact n |
|
| August 13, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Reports Second Quarter 2025 Financial Results (Unaudited) Net Revenue Increased 28% Year-Over-Year in Q2; Increased 27% Year-Over-Year in First Six Months of 2025 Announces Process to Evaluate Strategic Alternatives for its Tissue Health Plus, LLC Subsidiary FORT WORTH, TX, August 13, 2025 (GLOBE NEWSWIRE) - Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” |
|
| May 28, 2025 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorporat |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact |
|
| May 14, 2025 |
Exhibit 99.1 SANARA MEDTECH INC. INSIDER TRADING POLICY Background One of the principal purposes of the federal securities laws is the protection of investors in the U.S. securities markets through the assurance of fairness and the reduction of fraud in the markets. A major component of this effort is the prohibition on trading securities on the basis of or while in possession of material nonpubli |
|
| May 14, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) - Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and red |
|
| April 22, 2025 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 4, 2025 |
Exhibit 2.1 UNIT PURCHASE AGREEMENT THIS UNIT PURCHASE AGREEMENT (this “Agreement”) is dated as of April 1, 2025 by and among TISSUE HEALTH PLUS, LLC, a Delaware limited liability company (“Purchaser”), SANARA MEDTECH INC., a Texas corporation and the direct parent of Purchaser (“Parent”), CAREPICS, LLC, a Delaware limited liability company (the “Company”), the holders of the Company’s outstanding |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| March 25, 2025 |
EXHIBIT 21.1 Subsidiaries of Sanara MedTech Inc. The following is a list of subsidiaries of Sanara MedTech Inc., a Texas corporation (the “Company”), as of December 31, 2024, the states in which they are organized and the Company’s percentage ownership of the issued and outstanding stock or other equity interests for each entity. The names of particular subsidiaries may be omitted if the unnamed s |
|
| March 25, 2025 |
Exhibit 19.1 |
|
| March 25, 2025 |
Exhibit 10.20 FIRST AMENDMENT TO TERM LOAN AGREEMENT THIS FIRST AMENDMENT TO TERM LOAN AGREEMENT (this “Agreement”), dated as of March 19, 2025, is entered into among SANARA MEDTECH INC., a Texas corporation (“Borrower”), the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG SERVICING LLC, as administrative agent and collateral agent (the “Agent”). RECITALS WHEREAS, Borrower, th |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name |
|
| March 25, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| March 25, 2025 |
Exhibit 10.19 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACE WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL. January 16, 2025 (1) The parties listed in Schedule 1 (2) SANARA MEDTECH INC (3) THE RUSSELL REVOCABLE LIVING T |
|
| March 25, 2025 |
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited) Exhibit 99.1 Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited) Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) - Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing |
|
| January 22, 2025 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), executed to be effective as of January 15, 2025 (the “Effective Date”), is entered into by and between Sanara MedTech Inc., a Texas corporation (“Sanara”, the “Company”, or the “Employer”), and Michael D. McNeil (“Employee”). The Employer and Employee may be referred to singular |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| January 22, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd OsStic® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually(1); arrangement leverages Sanara’s existing call points and commercial infrastructure, and complements Sanara’s exis |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorp |
|
| January 22, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), executed to be effective as of January 15, 2025 (the “Effective Date”), is entered into by and between Sanara MedTech Inc., a Texas corporation (“Sanara”, the “Company”, or the “Employer”), and Elizabeth B. Taylor (“Employee”). The Employer and Employee may be referred to singularly as “Party” or collectively as “Parti |
|
| January 22, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, January 21, 2025 (GLOBE NEWSWIRE) – Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: |
|
| January 21, 2025 |
Exhibit 99.1 Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 Fourth Quarter Net Revenue Expected to Increase 45% to 48% Year-Over-Year; Full Year Net Revenue Expected to Increase 32% to 33% Year-Over-Year FORT WORTH, TX, January 21, 2025 (GLOBE NEWSWIRE) – Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company |
|
| January 21, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2025 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| December 4, 2024 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| December 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorp |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Ex |
|
| November 12, 2024 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| November 12, 2024 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Reports Third Quarter 2024 Results FORT WORTH, TX / GlobeNewswire / November 12, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcar |
|
| November 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| October 8, 2024 |
SMTI / Sanara MedTech Inc. / TALL PINES CAPITAL, LLC Passive Investment SC 13G 1 z108245sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SANARA MEDTECH INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 79957L100 (CUSIP Number) 09/30/24 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate t |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpo |
|
| October 7, 2024 |
Sanara MedTech Inc. Announces Changes to Its Board of Directors Exhibit 99.1 Sanara MedTech Inc. Announces Changes to Its Board of Directors FORT WORTH, TX / ACCESSWIRE / October 7, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets announ |
|
| September 23, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), executed to be effective September 1, 2024 (the “Effective Date”), is entered into by and between Sanara MedTech Inc., a Texas corporation (“Sanara”, the “Company”, or the “Employer”), and Ronald T. Nixon (“Employee”). The Employer and Employee may be referred to singularly as “Party” or collectively as “Parties”. WITN |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| September 11, 2024 |
Exhibit 99.1 Sanara MedTech Inc. and InfuSystem Holdings, Inc. Announce Exclusive United States Distribution Agreement with, and Minority Investment in, ChemoMouthpiece, LLC FORT WORTH, TX / GlobeNewswire / September 11, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on i |
|
| September 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of inco |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact n |
|
| August 12, 2024 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| August 12, 2024 |
Exhibit 10.4 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (“Agreement”) is made and entered into by Zachary Fleming (“Employee”) on the one hand, and Sanara MedTech Inc. (hereinafter “Company”) on the other hand, as of the date of the last of the Parties’ signatures, below. For purposes of this Agreement, Employee and Company are collectively referred to a |
|
| August 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| August 12, 2024 |
Exhibit 10.6 RESTRICTED STOCK AWARD AGREEMENT Sanara medtech inc. 2024 OMNIBUS LONG-TERM INCENTIVE PLAN 1. Grant of Award. Pursuant to the Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan (the “Plan”) for key Employees, key Consultants, and Outside Directors of Sanara MedTech Inc., a Texas corporation (the “Company”), (the “Participant”) has been granted a Restricted Stock Award in accord |
|
| August 12, 2024 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Announces Second Quarter 2024 Results FORT WORTH, TX / GlobeNewswire / August 12, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthca |
|
| August 12, 2024 |
Exhibit 10.7 FIRST AMENDMENT TO CONSULTING AGREEMENT THIS FIRST AMENDMENT TO CONSULTING AGREEMENT (this “Amendment”) is executed to be effective as of July 13, 2024 (the “Effective Date”) by and between Sanara MedTech Inc., a Texas corporation (the “Company”), and Ms. Ann Beal Salamone, an individual residing in Florida, for purposes of amending that certain Consulting Agreement executed to be eff |
|
| July 26, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Sanara MedTech Inc. |
|
| July 26, 2024 |
As filed with the Securities and Exchange Commission on July 26, 2024 As filed with the Securities and Exchange Commission on July 26, 2024 Registration No. |
|
| June 20, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpora |
|
| June 20, 2024 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| June 18, 2024 |
Exhibit 10.1 Sanara medtech inc. 2024 OMNIBUS LONG-TERM INCENTIVE PLAN The Sanara MedTech Inc. 2024 Omnibus Long-Term Incentive Plan (the “Plan”) was adopted by the Board of Directors of Sanara MedTech Inc., a Texas corporation (the “Company”), as of March 21, 2024, subject to approval by the Company’s shareholders. Article 1. PURPOSE The purpose of the Plan is to attract and retain the services o |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| June 17, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF FORMATION OF SANARA MEDTECH INC. ARTICLE ONE The name of the corporation is Sanara MedTech Inc. (the “Corporation”). ARTICLE TWO The Corporation is a for-profit corporation. ARTICLE THREE The purpose for which the Corporation is organized is the transaction of any or all lawful business for which a for-profit corporation may be incorporated under the |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 28, 2024 |
Sanara MedTech Inc. 1200 Summit Ave, Suite 414 Fort Worth, Texas 76102 Sanara MedTech Inc. 1200 Summit Ave, Suite 414 Fort Worth, Texas 76102 May 28, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services Washington, D.C. 20549 Attention: Abby Adams Re: Sanara MedTech Inc. Registration Statement on Form S-3 Filed on May 21, 2024 File No. 333-279592 (the “Registration Statement”) Request fo |
|
| May 21, 2024 |
As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No. |
|
| May 21, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 Sanara MedTech Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common Stock, $0.001 par value per share Rule 457(c) 255,049 $ 31.18 (2) $ 7,9 |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 13, 2024 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Announces First Quarter 2024 Results FORT WORTH, TX / GlobeNewswire / May 13, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare e |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact |
|
| May 13, 2024 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| April 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 17, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| April 18, 2024 |
Exhibit 10.1 TERM LOAN AGREEMENT dated as of April 17, 2024 among SANARA MEDTECH INC., as Borrower, the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, as Administrative Agent and Collateral Agent U.S. $55,000,000 Table of Contents Page SECTION 1 DEFINITIONS 1 1.01 Certain Defined Terms 1 1.02 Accounting Terms and Principles 2 |
|
| April 18, 2024 |
Sanara MedTech Inc. Announces $55 Million Debt Facility Exhibit 99.1 Sanara MedTech Inc. Announces $55 Million Debt Facility FORT WORTH, TX / GlobeNewswire / April 18, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare |
|
| April 18, 2024 |
Exhibit 10.2 SECURITY AGREEMENT dated as of April 17, 2024 among SANARA MEDTECH INC., as a Grantor, the other Grantors from time to time party hereto and CRG SERVICING LLC, as Administrative Agent and Collateral Agent Table of Contents Page Section 1. Definitions, Etc 1 1.01 Certain Uniform Commercial Code Terms 1 1.02 Additional Definitions 1 1.03 Other Defined Terms 3 Section 2. Representations |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), executed to be effective as of April 15, 2024 (the “Effective Date”), is entered into by and between Sanara MedTech Inc., a Texas corporation (“Sanara”, the “Company”, or the “Employer”), and Jake Waldrop (“Employee”). The Employer and Employee may be referred to singularly as “Party” or collectively as “Parties”. WITN |
|
| April 5, 2024 |
Exhibit 99.1 Sanara MedTech Inc. Announces the Appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer FORT WORTH, TX / GlobeNewswire / April 5, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developi |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 25, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| March 25, 2024 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| March 25, 2024 |
Exhibit 21.1 Subsidiaries of Sanara MedTech Inc. The following is a list of subsidiaries of Sanara MedTech Inc., a Texas corporation (the “Company”), as of December 31, 2023, the states in which they are organized and the Company’s percentage ownership of the issued and outstanding stock or other equity interests for each entity. The names of particular subsidiaries may be omitted if the unnamed s |
|
| March 25, 2024 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results FORT WORTH, TX / GlobeNewswire / March 25, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and re |
|
| March 25, 2024 |
Sanara MedTech Inc. Compensation Recovery Policy. Exhibit 97.1 SANARA MEDTECH INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) of Sanara MedTech Inc. (the “Company”) is hereby adopted as of November 13, 2023 in compliance with Rule 5608 of the Nasdaq Rules. Certain terms used herein shall have the meanings set forth in “Section 3. Definitions” below. Section 1. Recovery Requirement Subject to Section 4 of this P |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name |
|
| March 22, 2024 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SANARA MEDTECH INC. TABLE OF CONTENTS SECTION 1 OFFICES 1 SECTION 2 SHAREHOLDERS 1 2.1 Annual Meetings 1 2.2 Special Meetings 1 2.3 Place of Meetings 1 2.4 Notice of Meetings 2 2.4.1 General 2 2.4.2 Advance Notice of Shareholder Nominations 2 2.4.3 Advance Notice of Shareholder Proposals 5 2.5 Waiver of Notice 7 2.5.1 Waiver in Writing or by Electronic Tr |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpor |
|
| February 22, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| February 22, 2024 |
Exhibit 99.1 Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2023 FORT WORTH, TX / GlobeNewswire / February 22, 2024 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to |
|
| November 13, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| November 13, 2023 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Announces Third Quarter 2023 Results FORT WORTH, TX / GlobeNewswire / November 13, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthc |
|
| November 13, 2023 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Ex |
|
| September 19, 2023 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| September 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpo |
|
| August 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Emp |
|
| August 14, 2023 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact n |
|
| August 14, 2023 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Exhibit 99.1 Sanara MedTech Inc. Announces Second Quarter 2023 Results FORT WORTH, TX / GlobeNewswire / August 14, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthca |
|
| August 2, 2023 |
Exhibit 10.2 LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”) is executed effective as of August 1, 2023, by SANARA MEDTECH APPLIED TECHNOLOGIES, LLC, a Texas limited liability company (“Borrower”), whose address for purposes hereof is 1200 Summit Avenue, Suite 414, Fort Worth, Texas 76102, CADENCE BANK, a Mississippi state banking corporation (“Bank”), whose address for purposes hereof is 13 |
|
| August 2, 2023 |
Exhibit 2.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACE WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL. ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this “Agreement”) is dated as of August 1, 2023, by and among SanARA MEDTECH Applied technologies, llc, a Te |
|
| August 2, 2023 |
Exhibit 99.1 Sanara MedTech Inc. Announces the Acquisition of Certain Assets Related to its Collagen Products Business FORT WORTH, TX / GlobeNewswire / August 2, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies t |
|
| August 2, 2023 |
Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED AT THE APPROPRIATE PLACE WITH FIVE ASTERISKS [*****], HAS BEEN OMITTED IN RELIANCE ON REGULATION S-K, ITEM 601(B)(10)(IV) BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE THAT THE REGISTRANT TREATS AS CONFIDENTIAL. PROFESSIONAL SERVICES AGREEMENT THIS PROFESSIONAL SERVICES AGREEMENT (the “Agreement”) is signed by the Parties |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Empl |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 15, 2023 |
Sanara MedTech Inc. Announces First Quarter 2023 Results Exhibit 99.1 Sanara MedTech Inc. Announces First Quarter 2023 Results FORT WORTH, TX / GlobeNewswire / May 15, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare e |
|
| May 15, 2023 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 20, 2023 |
Exhibit 10.1.1 SANARA MEDTECH INC. RESTATED 2014 OMNIBUS LONG TERM INCENTIVE PLAN February 10, 2020 ARTICLE 1 General Purpose of Plan; Definitions 1.1 Name and Purposes. The name of this plan is the Sanara MedTech Inc. 2014 Omnibus Long Term Incentive Plan. The purpose of this Plan is to enable Sanara MedTech Inc. and its Affiliates to: (i) attract and retain skilled and qualified officers, employ |
|
| March 20, 2023 |
Exhibit 10.1.3 RESTRICTED STOCK AGREEMENT This RESTRICTED STOCK AGREEMENT (this “Agreement”) is entered into on , 202 (the “Date of Grant”), between SANARA MEDTECH INC., a Texas corporation (the “Company”) and (the “Recipient”). WHEREAS, the Board of Directors of the Company (the “Board”) has determined to grant restricted stock awards to non-employee directors of the Company under the Company’s 2 |
|
| March 20, 2023 |
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results Exhibit 99.1 Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results FORT WORTH, TX / GlobeNewswire / March 20, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and re |
|
| March 20, 2023 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| March 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name |
|
| March 20, 2023 |
Exhibit 10.1.4 RESTRICTED STOCK AGREEMENT This RESTRICTED STOCK AGREEMENT (this “Agreement”) is granted on March 2, 2023 (the “Date of Grant”), between SANARA MEDTECH INC., a Texas corporation (the “Company”) and (the “Recipient”). WHEREAS, the Board of Directors of the Company (the “Board”) has determined to grant restricted stock awards to certain Company employees and consultants under the Comp |
|
| March 20, 2023 |
Exhibit 10.15 TRANSACTION ADVISORY SERVICES AGREEMENT THIS TRANSACTION ADVISORY SERVICES AGREEMENT (this “Agreement”) is made as of March 1, 2023 (the “Effective Date”), by and between SANARA MEDTECH INC., a Texas corporation (the “Company”), and THE CATALYST GROUP, INC., a Texas corporation (“TCG”). WHEREAS, Catalyst Rochal, LLC (“CR”) is an affiliated entity of TCG, and CR owns shares of common |
|
| March 20, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| March 20, 2023 |
Exhibit 21.1 Subsidiaries of Sanara MedTech Inc. The following is a list of subsidiaries of Sanara MedTech Inc., a Texas corporation (the “Company”), as of December 31, 2022, the states in which they are organized and the Company’s percentage ownership of the issued and outstanding stock or other equity interests for each entity. The names of particular subsidiaries may be omitted if the unnamed s |
|
| February 24, 2023 |
Up to $75,000,000 Common Stock Sanara MedTech Inc. Filed pursuant to Rule 424(b)(5) Registration No. 333-251652 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 4, 2021) Up to $75,000,000 Common Stock Sanara MedTech Inc. We have entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) relating to shares of our common stock, $0.001 par value per share, offered by this p |
|
| February 24, 2023 |
Exhibit 1.1 Sanara MedTech Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement February 24, 2023 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Sanara MedTech Inc., a Texas corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows: 1. Issuance and |
|
| February 24, 2023 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| February 22, 2023 |
Exhibit 99.1 Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022 FORT WORTH, TX / GLOBENEWSWIRE / February 22, 2023 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| December 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| December 16, 2022 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| December 6, 2022 |
Exhibit 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE AND WAIVER 1. This Confidential Separation Agreement and General Release and Waiver (this ?Agreement?) is made between Shawn M. Bowman (?Employee?) and Sanara MedTech Inc. (?Employer?) (collectively the ?Parties? and each individually, a ?Party?). 2. Employee voluntarily resigned Employee?s position with Employer as President, Stra |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorp |
|
| November 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incor |
|
| November 30, 2022 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.1 |
|
| November 15, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (I |
|
| November 14, 2022 |
Earnings Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| November 14, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Ex |
|
| November 14, 2022 |
Sanara MedTech Inc. Announces Third Quarter 2022 Results Exhibit 99.1 Sanara MedTech Inc. Announces Third Quarter 2022 Results FORT WORTH, TX / GLOBENEWSWIRE / November 14, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic |
|
| August 26, 2022 |
Exhibit 99.3 FORM OF INCENTIVE STOCK OPTION GRANT NOTICE UNDER THE PRECISION HEALING INC. 2020 STOCK OPTION AND GRANT PLAN Pursuant to the Precision Healing Inc. 2020 Stock Option and Grant Plan (the ?Plan?), Precision Healing Inc., a Delaware corporation (together with any successor thereto, the ?Company?), has granted to the individual named below, an option (the ?Stock Option?) to purchase on o |
|
| August 26, 2022 |
EX-FILING FEES 9 ex107.htm Exhibit 107 Calculation of Filing Fee Tables FORM S-8 (Form Type) Sanara MedTech Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Eq |
|
| August 26, 2022 |
Exhibit 99.2 FORM OF NON-QUALIFIED STOCK OPTION GRANT NOTICE UNDER THE PRECISION HEALING INC. 2020 STOCK OPTION AND GRANT PLAN Pursuant to the Precision Healing Inc. 2020 Stock Option and Grant Plan (the ?Plan?), Precision Healing Inc., a Delaware corporation (together with any successor thereto, the ?Company?), has granted to the individual named below, an option (the ?Stock Option?) to purchase |
|
| August 26, 2022 |
Exhibit 99.5 NEITHER THIS WARRANT NOR THE SHARES (AS DEFINED BELOW) OF THE COMPANY ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER EITHER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STA |
|
| August 26, 2022 |
Exhibit 99.6 NEITHER THIS WARRANT NOR THE SHARES (AS DEFINED BELOW) OF THE COMPANY ISSUABLE UPON ITS EXERCISE HAVE BEEN REGISTERED UNDER EITHER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION AND MAY NOT BE SOLD, ASSIGNED, PLEDGED, HYPOTHECATED OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STA |
|
| August 26, 2022 |
As filed with the Securities and Exchange Commission on August 26, 2022 As filed with the Securities and Exchange Commission on August 26, 2022 Registration No. |
|
| August 15, 2022 |
Investor Presentation (furnished pursuant to Item 7.01). Exhibit 99.3 |
|
| August 15, 2022 |
Sanara MedTech Inc. Announces Second Quarter 2022 Results Exhibit 99.1 Sanara MedTech Inc. Announces Second Quarter 2022 Results FORT WORTH, TX / ACCESSWIRE / August 15, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, op |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact n |
|
| August 15, 2022 |
Earnings Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File N |
|
| July 15, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| July 5, 2022 |
Exhibit 2.1 MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (this ?Agreement?) is entered into as of July 1, 2022 (the ?Closing Date?), by and among Sanara MedTech Inc., a Texas corporation (?Purchaser?), Scendia Biologics, LLC, a Delaware limited liability company (the ?Company?), and Ryan Phillips (?Seller?). The Company, Seller and Purchaser are sometimes coll |
|
| July 5, 2022 |
Sanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition Exhibit 99.1 Sanara MedTech Inc. Announces Closing of Scendia Biologics, LLC Acquisition FORT WORTH, TX / July 5, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it closed |
|
| June 10, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpora |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact |
|
| May 16, 2022 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.1 |
|
| May 16, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorporat |
|
| May 16, 2022 |
Sanara MedTech Inc. Announces First Quarter 2022 Results EX-99.1 2 ex99-1.htm Exhibit 99.1 Sanara MedTech Inc. Announces First Quarter 2022 Results FORT WORTH, TX / May 16, 2022 / Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today its strategic, operational and financial results for the quar |
|
| April 29, 2022 |
DEF 14A 1 def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| April 29, 2022 |
Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?), executed to be effective as of January 1, 2022 (the ?Effective Date?), is entered into by and between Sanara MedTech Inc., a Texas corporation (?Sanara?, the ?Company?, or the ?Employer?), and Michael D. McNeil, an individual residing in Texas (?Employee?). The Employer and Employee may be referred to singularly as ?Pa |
|
| April 29, 2022 |
Exhibit 10.1 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?), executed to be effective as of January 1, 2022 (the ?Effective Date?), is entered into by and between Sanara MedTech Inc., a Texas corporation (?Sanara?, the ?Company? or the ?Employer?), and Zachary B. Fleming, an individual residing in Texas (?Employee?). The Employer and Emp |
|
| April 29, 2022 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| April 8, 2022 |
Exhibit 10.2 THE WARRANT EVIDENCED HEREBY, AND THE SECURITIES ISSUABLE HEREUNDER, HAVE BEEN AND SHALL BE ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) OR THE APPLICABLE STATE SECURITIES LAWS. THE WARRANT AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND SHALL NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECA |
|
| April 8, 2022 |
Exhibit 10.1 THE WARRANT EVIDENCED HEREBY, AND THE SECURITIES ISSUABLE HEREUNDER, HAVE BEEN AND SHALL BE ISSUED WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?) OR THE APPLICABLE STATE SECURITIES LAWS. THE WARRANT AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND SHALL NOT BE SOLD, TRANSFERRED, PLEDGED OR HYPOTHECA |
|
| April 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 8, 2022 |
Sanara MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc. Exhibit 99.1 Sanara MedTech Inc. Announces Closing of Merger to Acquire Precision Healing Inc. FORT WORTH, TX / April 4, 2022 / Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that it has closed the previously announced merger to ac |
|
| April 8, 2022 |
Exhibit 10.3 PRECISION HEALING INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the Plan is the Precision Healing Inc. 2020 Stock Option and Grant Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key Persons of Precision Healing Inc., a Delaware corporation (including |
|
| April 4, 2022 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG PRECISION HEALING INC., United Wound and Skin Solutions, LLC, Sanara Medtech Inc., PH MERGER SUB I, INC., PH MERGER SUB II, LLC, AND FURNEAUX CAPITAL HOLDCO, LLC (DBA BLUEIO) AS THE SECURITYHOLDERS? REPRESENTATIVE DATED AS OF APRIL 1, 2022 TABLE OF CONTENTS Page Section 1. DEFINITIONS. 2 1.1 Definitions 2 1.2 Other Definitions 18 Section 2. THE |
|
| April 4, 2022 |
Sanara MedTech Inc. Announces Entry into Merger Agreement to Acquire Precision Healing Inc. Exhibit 99.1 Sanara MedTech Inc. Announces Entry into Merger Agreement to Acquire Precision Healing Inc. FORT WORTH, TX / GlobeNewswire / April 4, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File Num |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name |
|
| March 31, 2022 |
Exhibit 21.1 Subsidiaries of Sanara MedTech Inc. Following is a list of subsidiaries of Sanara MedTech Inc., a Texas corporation, as of December 31, 2021, and the states in which they are organized. The indentation reflects the principal parenting of each subsidiary. The names of particular subsidiaries may be omitted if the unnamed subsidiaries, considered in the aggregate as a single subsidiary, |
|
| March 30, 2022 |
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results Exhibit 99.1 Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2021 Results FORT WORTH, TX / GlobeNewswire / March 30, 2022 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today i |
|
| March 30, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission File Number) (IRS Employe |
|
| March 30, 2022 |
Investor Presentation (furnished pursuant to Item 2.02). Exhibit 99.2 |
|
| March 28, 2022 |
Termination of a Material Definitive Agreement, Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpor |
|
| February 22, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| February 22, 2022 |
Exhibit 99.1 Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2021 FORT WORTH, TX / February 22, 2022 / Sanara MedTech Inc. (?Sanara? or the ?Company?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today certain unaudited preliminary results for the fourt |
|
| January 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 1, 2022 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incorpo |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| December 28, 2021 |
Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer Exhibit 99.1 Sanara MedTech Inc. Announces the Appointment of Zachary B. Fleming as Chief Executive Officer FORT WORTH, TX / December 28, 2021 / Sanara MedTech Inc. (?Sanara? or the ?Company?) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary (?Zach?) B. Fleming has been appointed Chief |
|
| December 22, 2021 |
Retirement Agreement, dated December 22, 2021, between Sanara MedTech Inc. and J. Michael Carmena. Exhibit 10.1 RETIREMENT AGREEMENT THIS RETIREMENT AGREEMENT (the ?Agreement?) is dated effective as of December 22, 2021 (the ?Effective Date?) between J. MICHAEL CARMENA (?Carmena?) and SANARA MEDTECH INC. (?Sanara?). Carmena and Sanara are sometimes hereinafter referred to individually as a ?Party? and together as the ?Parties?. WHEREAS, Carmena is currently an employee of Sanara and serves as V |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| December 22, 2021 |
EX-99.1 3 ex99-1.htm Exhibit 99.1 Sanara MedTech Inc. Announces the Retirement of J. Michael Carmena and Appointment of Eric Tanzberger to its Board of Directors FORT WORTH, TX / December 22, 2021 / Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorp |
|
| December 15, 2021 |
Sanara MedTech Inc. Announces the Appointment of Roszell Mack III to its Board of Directors EX-99.1 2 ex99-1.htm Exhibit 99.1 Sanara MedTech Inc. Announces the Appointment of Roszell Mack III to its Board of Directors FORT WORTH, TX / December 15, 2021 (Globe Newswire) - Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Roszell Mack III h |
|
| November 15, 2021 |
Investor Presentation (furnished pursuant to Item 2.02). EXHIBIT 99.2 |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS E |
|
| November 15, 2021 |
Sanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update EXHIBIT 99.1 Sanara MedTech Inc. Announces Third Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE / November 12, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, op |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Ex |
|
| September 30, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| September 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| September 23, 2021 |
Investor Presentation (furnished pursuant to Item 7.01). EXHIBIT 99.1 |
|
| September 13, 2021 |
Letter dated September 9, 2021 from MaloneBailey, LLP to the Securities and Exchange Commission. EXHIBIT 16.1 |
|
| September 13, 2021 |
DEFA14A 1 smtidefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| September 13, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission (IRS Employer incor |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| August 16, 2021 |
Investor Presentation (furnished pursuant to Item 2.02). EXHIBIT 99.2 |
|
| August 16, 2021 |
SANARA MEDTECH INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS EXHIBIT 99.1 Sanara MedTech Inc. Announces Second Quarter 2021 Results and Business Update FORT WORTH, TX / ACCESSWIRE / Aug 16, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today its strategic, operat |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction (Commission (IRS Employer of incorpo |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTECH INC. (Exact n |
|
| August 16, 2021 |
EXHIBIT 10.1 MODIFICATION AGREEMENT THIS MODIFICATION AGREEMENT (this ?Agreement?) is executed effective as of the 29th day of June 2021, by SANARA MEDTECH INC., a Texas corporation (?Borrower?), CELLERATE, LLC, a Texas limited liability company (?Cellerate?), and UNITED WOUND AND SKIN SOLUTIONS, LLC, a Delaware limited liability company (?UWS Solutions?), and CADENCE BANK, N.A., a national bankin |
|
| August 6, 2021 |
Other Events, Shareholder Director Nominations, Shareholder Director Nominations 8-K 1 smti8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (C |
|
| July 19, 2021 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (Agreement) is effective this 1st day of July 2021 and entered into between Sanara MedTech Inc, a Texas corporation ("Company") located at 1200 Summit Ave, Suite 414, Fort Worth, TX 76102, and Ann Beal Salamone, ("Consultant") located at 12719 Cranes ML, San Antonio, TX 78230. RECITALS Company is a provider of wound and skin care products |
|
| July 19, 2021 |
Sanara MedTech Inc. Announces the Purchase of Certain Assets from Rochal Industries, LLC Exhibit 99.1 Sanara MedTech Inc. Announces the Purchase of Certain Assets from Rochal Industries, LLC FORT WORTH, TX / ACCESSWIRE / July 19, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today the acqui |
|
| July 19, 2021 |
Exhibit 10.1 ASSET PURCHASE AGREEMENT This ASSET PURCHASE AGREEMENT (as amended, restated, modified or supplemented from time to time, this ?Agreement?) is executed this 14th day of July, 2021, but to be effective July 1, 2021 (the ?Effective Date?), by and among Sanara MedTech Inc., a Texas corporation (?Purchaser?) and Rochal Industries, LLC, a Texas limited liability company (?Seller?). Purchas |
|
| July 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Emplo |
|
| June 4, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Employ |
|
| June 4, 2021 |
Exhibit 99.1 Sanara MedTech Inc. Announces Exclusive Partnership with Pixalere Healthcare Inc. to Advance its Comprehensive Wound and Skin Care Strategy FORT WORTH, TX / ACCESSWIRE / June 4, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of surgical and chronic wound care products dedicated to imp |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39678 SANARA MEDTE |
|
| March 30, 2021 |
Exhibit 4.1 DESCRIPTION OF SECURITIES Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) has common stock registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following is a brief description of the terms of our capital stock. This summary does not purport to be complete in all respects. This description is subject to, and qualified in its entirety by |
|
| March 30, 2021 |
Subsidiaries of Sanara MedTech Inc. Exhibit 21.1 Subsidiaries of Sanara MedTech Inc. 1. Cellerate, LLC, a Texas a limited liability company 2. Wound Care Innovations, LLC, a Nevada limited liability company 3. United Wound and Skin Solutions, LLS, a Delaware limited liability company 4. Pixalere Healthcare USA, LLC, a Delaware limited liability company 5. Sanara Pulsar, LLC, a Texas limited liability company 6. Sanara Biologics, LLC |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 - Commission File Number 001-39678 SANARA MEDTECH INC. (Exact name of Registrant as specified in its charter) Texas 59-2219994 (State or other jurisdiction of incorporation or organization) (I. |
|
| March 30, 2021 |
Exhibit 10.1.2 RESTRICTED STOCK AGREEMENT RESTRICTED STOCK AGREEMENT (the ?Agreement?) granted on [ Insert Date ], between SANARA MEDTECH INC., a Texas corporation (the ?Company?) and [ Insert Name ] (the ?Recipient?). WHEREAS, the Board of Directors of the Company has determined to grant restricted stock awards to certain Company employees under the Company?s 2014 Omnibus Long Term Incentive Plan |
|
| March 30, 2021 |
Exhibit 3.1 ARTICLES OF INCORPORATION OF SANARA MEDTECH INC. (as amended through December 30, 2020) The undersigned natural person, of the age of eighteen years or more, a resident of the State of Texas, acting as an incorporator of a corporation under the Texas Business Corporation Act, does hereby adopt the following Articles of Incorporation for such corporation: ARTICLE ONE The name of the Cor |
|
| February 23, 2021 |
Exhibit 99.1 |
|
| February 23, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS E |
|
| February 17, 2021 |
Exhibit 99.3 Sanara MedTech Inc. Announces Closing of $31.6 Million Public Offering and Full Exercise of the Underwriters? Option to Purchase Additional Shares FORT WORTH, TX / ACCESSWIRE / February 17, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of wound and skin care products dedicated to imp |
|
| February 17, 2021 |
Sanara MedTech Inc. Announces Pricing of Public Offering Exhibit 99.2 Sanara MedTech Inc. Announces Pricing of Public Offering FORT WORTH, TX / ACCESSWIRE / February 12, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (?Sanara,? the ?Company,? ?we,? ?our? or ?us?) (NASDAQ: SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, today announced the pricing of its underwritten public offering o |
|
| February 17, 2021 |
Sanara MedTech Inc. Announces Proposed Public Offering of Common Stock Exhibit 99.1 Sanara MedTech Inc. Announces Proposed Public Offering of Common Stock FORT WORTH, TX / ACCESSWIRE / February 11, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, today announced that it intends to offer shares of |
|
| February 17, 2021 |
Exhibit 1.1 Execution SANARA MEDTECH INC. 1,100,000 Shares of Common Stock (par value $0.001 per share) Underwriting Agreement February 12, 2021 Cantor Fitzgerald & Co. As Representative of the several Underwriters listed in Schedule A hereto c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Sanara MedTech Inc., a Texas corporation (the ?Company?), proposes to is |
|
| February 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS E |
|
| February 16, 2021 |
1,100,000 Shares of Common Stock Sanara MedTech Inc. 424B5 1 form424b5.htm Filed pursuant to Rule 424(b)(5) Registration No. 333-251652 PROSPECTUS SUPPLEMENT (To Prospectus Dated January 4, 2021) 1,100,000 Shares of Common Stock Sanara MedTech Inc. We are offering 1,100,000 shares of common stock of Sanara MedTech Inc. Our common stock is currently listed on The Nasdaq Capital Market under the symbol “SMTI.” On February 11, 2021, the last reported s |
|
| February 11, 2021 |
SUBJECT TO COMPLETION, DATED FEBRUARY 11, 2021 424B5 1 form424b5.htm Filed pursuant to Rule 424(b)(5) Registration No. 333-251652 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell th |
|
| February 1, 2021 |
Exhibit 10.1 SUBLICENSE AGREEMENT This Sublicense Agreement (this “Agreement”) is entered into August 27, 2018, and shall become effective the 28th day of August, 2018, (the “Effective Date”), by and between CGI Cellerate RX, LLC, a Texas limited liability company, having its principle place of business at 12000 Network Blvd, Suite B-200, San Antonio, TX 78249 (“Sublicensor”), and Cellerate, LLC, |
|
| February 1, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Em |
|
| February 1, 2021 |
EX-10.3 4 smtiex10-3.htm SECOND AMENDMENT OF SUBLICENSE AGREEMENT Exhibit 10.3 SECOND AMENDMENT OF SUBLICENSE AGREEMENT THIS SECOND AMENDMENT OF SUBLICENSE AGREEMENT (this "First Amendment") is executed as of January 26, 2021, by and between CGI Cellerate RX, LLC, a Texas limited liability company, having its principle place of business at 7500 Rialto Boulevard, Building II, Suite 220, Austin, TX |
|
| February 1, 2021 |
Exhibit 10.2 FIRST AMENDMENT OF SUBLICENSE AGREEMENT THIS FIRST AMENDMENT OF SUBLICENSE AGREEMENT (this "First Amendment") is executed as of May 31 2019, by and between CGI Cellerate RX, LLC, a Texas limited liability company, having its principle place of business at 7500 Rialto Boulevard, Building II, Suite 220, Austin, TX 78735 (“Sublicensor”), and Cellerate, LLC, a Texas limited liability comp |
|
| January 25, 2021 |
Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020 Sanara MedTech Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2020 FORT WORTH, TX / ACCESSWIRE / January 25, 2021 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of wound and skin care products dedicated to improving patient outcomes, announced today certain unaudited preliminary results for the f |
|
| January 25, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Em |
|
| January 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2021 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 001-39678 59-2219994 (State or other jurisdiction of (Commission File Number) (IRS Em |
|
| January 22, 2021 |
Exhibit 10.1 LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”) is executed effective the 15th day of January 2021, by SANARA MEDTECH INC., a Texas corporation (“Borrower”), CELLERATE, LLC, a Texas limited liability company (“Cellerate”), and UNITED WOUND AND SKIN SOLUTIONS, LLC, a Delaware limited liability company (“UWS Solutions”), and CADENCE BANK, N.A., a national banking association (“Ban |
|
| December 30, 2020 |
CORRESP 1 filename1.htm Sanara MedTech Inc. 1200 Summit Ave, Suite 414 Fort Worth, Texas 76102 December 30, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Attention: Tim Buchmiller Re: Sanara MedTech Inc.Registration Statement on Form S-3 Filed on December 23, 2020 File No. 333-251652 (the “Registration Statement”) Request for Accelera |
|
| December 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2020 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 000-11808 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| December 23, 2020 | ||
| December 23, 2020 |
As filed with the Securities and Exchange Commission on December 23, 2020 Registration No. |
|
| November 16, 2020 |
As filed with the Securities and Exchange Commission on November 16, 2020 Registration No. |
|
| November 13, 2020 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39678 SANARA MED |
|
| November 13, 2020 |
Exhibit 10.1 AMENDMENT No. 1 TO EXCLUSIVE LICENSE AGREEMENT (BIAKOS Antimicrobial Skin/Wound Cleanser and Gel) This Amendment No. 1 (this (“Amendment”) to Exclusive License Agreement, dated July 7, 2019, by and between Rochal Industries, LLC, a Texas limited liability company, having its principal place of business at 12000 Network Blvd, B-200, San Antonio, TX 78249 (“Licensor”), and Sanara MedTec |
|
| October 29, 2020 | ||
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 59-2219994 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1200 |
|
| October 29, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2020 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 000-11808 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| October 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 12, 2020 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 000-11808 59-2219994 (State or other jurisdiction of incorporation) (Commission File |
|
| October 16, 2020 |
Sanara MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board of Directors Exhibit 99.1 Sanara MedTech Inc. Announces the Appointment of Bob DeSutter to Its Board of Directors FORT WORTH, TX / ACCESSWIRE / October 15, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (OTCQB:SMTI), a provider of wound and skin care products and virtual consult services dedicated to improving patient outcomes, announced today that Bob De |
|
| October 14, 2020 |
Submission of Matters to a Vote of Security Holders - AMENDED CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2020 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 000-11808 59-2219994 (State or other jurisdiction of incorporation) ( |
|
| August 13, 2020 |
Quarterly Report - QUARTERLY REPORT U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 0-11808 SANARA MEDTECH INC. (Exact name of registrant as specified i |
|
| July 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2020 SANARA MEDTECH INC. (Exact name of registrant as specified in its charter) Texas 000-11808 59-2219994 (State or other jurisdiction of incorporation) (Commission File Numb |
